Despite the fact that human adenovirus (HAdV) causes severe infections in immunosuppressed and immunocompetent individuals, especially in children, there is currently no specific treatment for these infections. Previously we reported a new salicylamide analogue, JMX0312, as a potent inhibitor of HAdV infection with low cytotoxicity in vitro. Here we evaluate the in vivo efficacy and safety of this molecule in the immunosuppressed Syrian hamster model of HAdV infection. JMX0312 administration at a dose of 6.25 mg/kg did not affect the body weight of the animals, and reduced the viral load in liver and blood in a similar way than cidofovir. Also, JMX0312 reduced the mortality of the animals, although in a lesser extent than cidofovir, a drug used to treat these infections that must be subject to rigorous monitoring due to its high toxicity and whose used is not approved in children. Our findings highlight the potential of this new antiviral agent for the treatment of HAdV infections, paving the way for future pre-clinical and clinical trial development towards a safer and more effective treatment against HAdV-associated infections.

Keywords: Adenovirus; Antiviral drugs; Immunosuppression; JMX0312; Niclosamide; Syrian hamster.

Copyright © 2025. Published by Elsevier B.V.

尽管人腺病毒（HAdV）可导致免疫抑制和免疫功能正常个体，尤其是儿童的严重感染，但目前尚无针对这些感染的具体治疗方法。此前我们报道了一种新的水杨酰胺类似物JMX0312，在体外实验中表现出对HAdV感染的强大抑制作用且细胞毒性较低。本文评估了该分子在免疫抑制叙利亚仓鼠模型中的体内疗效和安全性。

给予6.25 mg/kg剂量的JMX0312并未影响动物体重，并以与cidofovir相似的方式降低了肝脏和血液中的病毒载量。此外，JMX0312还减少了动物死亡率，尽管其效果略逊于cidofovir（用于治疗这些感染的一种药物），由于其高毒性，该药物的使用必须受到严格监控，在儿童中也未被批准使用。

我们的研究结果突显了这种新型抗病毒剂在HAdV感染治疗中的潜力，并为未来临床前和临床试验的发展铺平道路，从而寻求更安全、更有效的针对与HAdV相关感染的治疗方法。

关键词：腺病毒；抗病毒药物；免疫抑制；JMX0312；尼克洛胺；叙利亚仓鼠。

版权 © 2025. 出版社：Elsevier B.V.